Are you Dr. Cohen?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 42 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
5777 E Mayo Blvd
Phoenix, AZ 85054Phone+1 480-342-4800Fax+1 602-301-8572
Summary
- Dr. Peter Cohen, MD is an oncologist in Phoenix, Arizona. He is currently licensed to practice medicine in Arizona, Ohio, and Maryland. He is affiliated with Mayo Clinic Hospital.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
Geisel School of Medicine at DartmouthClass of 1979
Certifications & Licensure
AZ State Medical License 2008 - 2022
OH State Medical License 1998 - 2009
MD State Medical License 1989 - 1998- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 646 citationsIntracellular oxidation-reduction states in vivo.Britton Chance, Peter A. Cohen, Frans F. Jöbsis, Brigitte Schoener
Science. 1962-08-17 - 225 citationsImmune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccineVani Lakshminarayanan, Pamela Thompson, Margreet A. Wolfert, Therese Buskas, Judy M. Bradley
Proceedings of the National Academy of Sciences of the United States of America. 2012-01-03 - 40 citationsA Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or LymphomaDonald W. Northfelt, Ramesh K. Ramanathan, Peter A. Cohen, Daniel D. Von Hoff, Glen J. Weiss
Clinical Cancer Research. 2014-07-15
Press Mentions
Researchers Find Cancer-Fighting Drugs Help Morbidly Obese Mice Lose WeightJanuary 17th, 2017
Grant Support
- Sunitinib Modulation Of Cancer ImmunotherapyNational Cancer Institute2010–2012
- Role Of Macrophage Regulatory Cells (Mac-Regs) In Immune RegulationNational Institute Of Allergy And Infectious Diseases2011
- Optimized Ex Vivo Expansion Of Anti-Tumor TH1 And TC1 For Adoptive Immunotherapy.National Cancer Institute2009–2010
- Proliferative Conditioning Of Tumor-Competent Dendritic Cell PrecursorsNational Cancer Institute2008–2010
- Proliferative Conditioning Of Tumor-Competent Dendritic Cell PrecursorsNational Cancer Institute2007–2008
- CD8+ Helper-Independent T Cells In Tumor TherapyNational Cancer Institute2004–2007
- CD8+ Helper Independent T Cells In Tumor TherapyNational Cancer Institute2001–2003
Professional Memberships
- Member
